Novartis Revamps, Buys GSK Cancer Drugs, Sells Animal Health To Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is overhauling its pharma business by exchanging selected assets with GlaxoSmithKline and divesting its animal health business to Eli Lilly. Worth more than $25 billion, the complex corporate deal will boost the Swiss group’s oncology unit and create a consumer health joint venture, while divesting its vaccine unit to GSK.